EGFR and non-small cell lung carcinoma: In NSCLC, β-catenin levels are increased in the cells harboring oncogenic EGFR mutations, as well as in gefitinib-resistant cells, and inhibition of the Wnt/β-catenin pathway re-sensitized cells to EGFR inhibitors and increased their efficacy [13,14,15].